By Drug Class / Mechanism

Liposomal / Extended-Release Formulations Market Analysis

Cross-industry research covering Liposomal / Extended-Release Formulations across 1 market reportspanning Pharmaceuticals / Medical Devices — Regional Anesthesia.

1 Reports

1 Industries

Reports Covering Liposomal / Extended-Release Formulations

Nerve Blocks Market to Reach USD 9.4 Billion by 2033 at 6.4% CAGR

Pharmaceuticals / Medical Devices — Regional Anesthesia·Market: USD 5.7 Billion (2025)·CAGR: 6.4%

Liposomal bupivacaine (Exparel) is the primary commercial product in this class, commanding a significant WAC premium over plain bupivacaine. However, under our base case, 503B compounded bupivacaine erosion and evolving meta-analytic evidence questioning incremental efficacy over plain bupivacaine with epinephrine will compress this segment's net price realization. IRA negotiation is not directly applicable to this small-molecule-derived product, but CMS site-neutral payment reforms and ASC bundled payment evolution pose indirect reimbursement risk.

16%

Market Share

7.8%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments